Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
INTerpath-002
Phase 3 Recruiting
868 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Phase 3 Recruiting
306 enrolled
TIGOS-LS
Phase 2 Recruiting
250 enrolled
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Phase 1/2 Recruiting
183 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
PrE0510
Phase 2 Recruiting
60 enrolled
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
170 enrolled
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Phase 3 Recruiting
420 enrolled
ECHELON
Phase NA Recruiting
280 enrolled
NIBCUN
Phase 2 Recruiting
36 enrolled
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 Recruiting
300 enrolled
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
225 enrolled
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/2 Recruiting
554 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Phase 1/2 Recruiting
45 enrolled
NUMER
Phase 2 Recruiting
120 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Phase 3 Recruiting
530 enrolled
ALBORAN
Phase 3 Recruiting
70 enrolled
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 Recruiting
150 enrolled
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
680 enrolled
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
Phase NA Recruiting
48 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Phase 1 Recruiting
180 enrolled
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
66 enrolled
Dabrafenib and/or Trametinib Rollover Study
Phase 4 Recruiting
100 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
THIO Sequenced With Cemiplimab in Advanced NSCLC
Phase 2 Recruiting
227 enrolled
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
Phase 1/2 Recruiting
324 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Phase 3 Recruiting
750 enrolled
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Phase 1 Recruiting
30 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
85 enrolled
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
124 enrolled
GASTIVA
Phase 4 Recruiting
5,384 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
MOONRAY-01
Phase 1 Recruiting
630 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
Be6A Lung-02
Phase 3 Recruiting
714 enrolled
MK-6070-002
Phase 1/2 Recruiting
262 enrolled